hospital

Repros Therapeutics says positive results from Phase II trial of uterine fibroids drug; shares jump

pharmafile | April 15, 2016 | News story | Medical Communications, Research and Development |ย ย Repros Therapeutics, Shares, US FDA, drug trial, uterine fibroidsย 

Shares in Repros Therapeutics (Nasdaq: RPRX) surged to close over 18% Thursday after the company announced positive mid-stage trial results for its drug candidate to treat uterine fibroids.

The company said the trial showed its Proellex significantly reduced excessive menstrual bleeding in women with uterine fibroids. The company will now work with the US Food and Drug Administration (FDA) to plan a Phase III trial.

Repros Therapeutics is engaged in the development of new drugs to treat hormonal and reproductive system disorders.

Advertisement

Shares in the company closed up 18.7% at $2.67 Thursday on the Nasadq.

Anjali Shukla

Related Content

Uterine fibroids and the cost of silence

By Tina Backhouse Stigma and shame Every month, most women on the planet have a …

Pfizer and Myovantโ€™s menstrual blood loss treatment reports 78% effectiveness

Pfizer and Myovant Scienceโ€™s relugolix treatment to reduce menstrual blood loss in women with uterine …

19199400883_6db786ce0d_b

Lawsuit against FDA claims Bernie Sanders played role in approval of rival drug

Catalyst Pharmaceutical is attempting to show in court that pressure from US Senator Bernie Sanders …

The Gateway to Local Adoption Series

Latest content